Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 14/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 14/20 | 0.77 |
| ▸ | HSP90AA1 | P07900 | 5/20 | 0.77 |
| ▸ | NPC1 | O15118 | 12/20 | 0.74 |
| ▸ | CD74 | P04233 | 1/20 | 0.73 |
| ▸ | MIF | P14174 | 1/20 | 0.73 |
| ▸ | RAB9A | P51151 | 8/20 | 0.71 |
| ▸ | POLB | P06746 | 3/20 | 0.71 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.71 |
| ▸ | AGTR1 | P30556 | 4/20 | 0.65 |
| ▸ | ECE2 | P0DPD6 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 4/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.64 |
| ▸ | HTT | P42858 | 3/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | PKM | P14618 | 1/20 | 0.64 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.64 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.64 |
| ▸ | RELA | Q04206 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8344151 | 0.84 | CD74 (1.00) | MEN1KMT2AHSP90AA1NPC1CD74 | |
| SCHEMBL12281444 | 0.84 | MEN1 (0.68) | MEN1KMT2AHSP90AA1NPC1CD74 | |
| SCHEMBL14681376 | 0.84 | KMT2A (0.68) | MEN1KMT2AHSP90AA1NPC1CD74 | |
| SCHEMBL12280972 | 0.84 | MEN1 (1.00) | MEN1KMT2AHSP90AA1NPC1CD74 | |
| SCHEMBL9152459 | 0.83 | MEN1 (0.67) | MEN1KMT2AHSP90AA1NPC1CD74 | |
| SCHEMBL3319480 | 0.83 | CD74 (0.79) | MEN1KMT2AHSP90AA1NPC1CD74 | |
| SCHEMBL3317100 | 0.83 | CD74 (0.79) | MEN1KMT2AHSP90AA1NPC1CD74 | |
| SCHEMBL14426523 | 0.82 | MEN1 (0.72) | MEN1KMT2AHSP90AA1NPC1CD74 | |
| SCHEMBL6428720 | 0.81 | CD74 (0.77) | MEN1KMT2AHSP90AA1NPC1CD74 | |
| SCHEMBL28200632 | 0.81 | CD74 (0.77) | MEN1KMT2AHSP90AA1NPC1CD74 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080280849-A1 | Synergic Combinations Comprising a Quinoline Compound and Other Hiv Infection Therapeutic Agents | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2008-11-13 | — | — | US | claimed |
| US-6670377-B1 | Inhibitory properties of human immunodeficiency virus integrase | CENTRE NATIONAL DE LA RECHERCHE (FR) | 2003-12-30 | — | — | US | claimed |
| US-20250213569-A1 | METHODS AND COMPOSITIONS FOR MEASURING AND INHIBITING EXONUCLEASE ACTIVITY | NEW YORK UNIVERSITY (US) | 2025-07-03 | — | — | US | disclosed |
| WO-2022140581-A1 | METHODS AND COMPOSITIONS FOR MEASURING AND INHIBITING EXONUCLEASE ACTIVITY | NEW YORK UNIVERSITY (US) | 2022-06-30 | — | — | WO | disclosed |
| EP-0975597-B1 | QUINOLINE DERIVATIVES, HAVING IN PARTICULAR ANTIVIRAL PROPERTIES, PREPARATION AND BIOLOGICAL APPLICATIONS THEREOF | CENTRE NAT RECH SCIENT (FR) | 2009-09-02 | — | — | EP | disclosed |
| US-20080280849-A1 | Synergic Combinations Comprising a Quinoline Compound and Other Hiv Infection Therapeutic Agents | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2008-11-13 | — | — | US | disclosed |
| US-6670377-B1 | Inhibitory properties of human immunodeficiency virus integrase | CENTRE NATIONAL DE LA RECHERCHE (FR) | 2003-12-30 | — | — | US | disclosed |
| EP-0975597-A1 | QUINOLINE DERIVATIVES, HAVING IN PARTICULAR ANTIVIRAL PROPERTIES, PREPARATION AND BIOLOGICAL APPLICATIONS THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2000-02-02 | — | — | EP | disclosed |
| WO-1998045269-A1 | QUINOLINE DERIVATIVES, HAVING IN PARTICULAR ANTIVIRAL PROPERTIES, PREPARATION AND BIOLOGICAL APPLICATIONS THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 1998-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280849-A1 | Synergic Combinations Comprising a Quinoline Compound and Other Hiv Infection Therapeutic Agents | CTSL, CDKL1, QTRT2 | MEN1 3557/4885KMT2A 1290/4885HSP90AA1 4060/4885 |
| US-20250213569-A1 | METHODS AND COMPOSITIONS FOR MEASURING AND INHIBITING EXONUCLEASE ACTIVITY | DCLRE1B, RNASE1, ADAR | MEN1 3464/4885KMT2A 4125/4885HSP90AA1 3486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.